TATVA - Tatva Chintan Pharma Chem Limited Share Price

In the Q3 FY 2026 earnings call, Tatva Chintan Pharma Chem Limited's management provided an optimistic outlook for the company amid signs of stabilization in the chemical industry. The company reported operating revenue of INR 1,313 million, a 53% year-on-year increase, and EBITDA of INR 255 million, reflecting a remarkable 261% year-on-year growth.

Key forward-looking points from the management include:

1. Revenue Growth Expectations: Management anticipates a growth of 20% to 30% for FY 2026 and a similar outlook for FY 2027. Based on the current trajectory, they foresee reaching overall revenue levels of INR 850 to 900 crores within the next 2.5 to 3 years.

2. Sector-Specific Strategies:

   • Phase Transfer Catalysts: Remain steady due to strong customer relationships.
   • Structured Directing Agents (SDA): Anticipation of a 25% to 30% growth as major automotive regulations, including Euro 7, come into effect.
   • Pharma & Agro Intermediates: New products are expected to contribute significantly, projected to bring in INR 200-250 crores in revenue by FY 2027 and INR 150 crores by FY 2028.

3. New Plant Developments: The company plans to break ground on a new plant at Jolva, Dahej, with a capex of INR 250-275 crores, vital for scaling up agro products, anticipated to be completed within 18 months.

4. Commercialization of Semiconductor Chemicals: Initiating plant trial orders for semiconductor chemicals is noted as a future growth opportunity, with expectations for significant contributions post-2028.

5. Margin Outlook: EBITDA margins are expected to stabilize between 20% and 22%, driven by operational efficiencies and the introduction of innovative technologies.

The management expressed confidence in executing customer commitments while navigating geopolitical uncertainties and maintaining a focus on building infrastructure for future growth.

Major Q&A from the Earnings Call Transcript

1. Question: "I want to get first update on the new plant we were planning to commercialize, where are we in that plant?"
Answer: We have completed the engineering work, and the plant has been handed over to production. We are conducting water trials now and expect chemical trials to start on February 1, with validation trials commencing on February 16. We anticipate the plant will be ready for commercial production in the first week of March.

2. Question: "How do you see the crop protection market because we are betting heavily on it for our growth?"
Answer: Our approach is distinct as we have focused on innovative, catalytic technologies rather than conventional methods. We believe that 2026 will mirror 2025 in terms of demand, with positive growth anticipated from 2027 onward, as we will introduce new agro products.

3. Question: "Can you provide any details on capex plans for the new Jolva plant?"
Answer: The first phase of the Jolva plant has a capex of around INR 250-275 crores, which we plan to execute over 18 months. This facility will significantly enhance our operational capabilities for agro intermediates, tapping into strong domestic demand.

4. Question: "What can we expect in terms of revenue from the Semiconductor Chemicals segment?"
Answer: We're starting with our first plant-scale order and expect materialization of sales but anticipate a gradual ramp-up to full commercialization by 2028.

5. Question: "Are we seeing any impact from the new regulations in the Structured Directing Agents (SDA) market?"
Answer: Yes, we have begun to see increased demand from Euro 7 regulations, anticipating a growth rate of around 25-30%. We expect to onboard additional customers soon.

6. Question: "Can you guide us on your financial growth expectations for FY '26 and FY '27?"
Answer: We're targeting a growth range of 20% to 30% for FY '26, and a similar range for FY '27, particularly influenced by our new Jolva plant operational impact expected around September or October 2027.

7. Question: "What EBITDA margin can we realistically expect going forward?"
Answer: We anticipate EBITDA margins in the range of 20% to 22%, with potential for higher margins if raw material prices stabilize and improve.

8. Question: "What is our expected revenue from agro intermediates in FY '27?"
Answer: We foresee potential revenue of about INR 200-250 crores from our new agro intermediates, ramping up significantly in FY '28 as commercialization solidifies.